Dow Jones received a payment from EQS/DGAP to publish this press release.
Sartorius Stedim Biotech SA: Key Figures on 9-Month Business Development in
2017
16-Oct-2017 / 21:17 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Disclosure of an inside information according to Article 17 MAR
Key Figures on 9-Month Business Development in 2017
? Business performance temporary weaker than expected
? Full-year 2017 guidance adjusted accordingly
? Mid-term outlook and targets remain unchanged
Aubagne, France, October 16, 2017 - Sartorius Stedim Biotech, a leading
supplier for the biopharmaceutical industry, today pre-announced results for
the first nine months 2017. Based on preliminary figures sales revenue grew
by 3.3% in constant currencies to approximately EUR806 million (reported:
+2.7%), while its underlying EBITDA1 margin reached 26.8% (9M 2016: 27.3%).
Business performance in the first nine months was influenced by some
concurrent, temporary effects: demand was relatively soft in some regions,
partly as a result of customer inventory destocking. Moreover, no deliveries
were possible from the company's facility in Puerto Rico immediately after
Hurricane Maria, although production has now been resumed. I n addition,
ongoing restrictions in a partner's capacity to supply cell culture has
affected the business longer than expected.
Management assumes that these factors will also influence business
development for the full-year of 2017. Therefore, Sartorius Stedim Biotech
now expects that sales revenue in constant currencies will increase by
approximately 4% (previous guidance: approx. 8% to 12%). The underlying
EBITDA1 margin in constant currencies is now projected to reach approx. the
prior-year level of 27.5% (previous guidance: approx. +0.5 percentage points
vs. FY 2016).
Sartorius Stedim Biotech confirms its mid-term targets.
Further information will be published on October 25, 2017.
1 Underlying EBITDA = earnings before interest, taxes, depreciation and
amortization, and adjusted for extraordinary items
This publication contains statements about the future development of the
Sartorius Stedim Biotech Group. We cannot guarantee that the content of
these statements will actually apply because these statements are based upon
assumptions and estimates that harbor certain risks and uncertainties.
Contact
Petra Kirchhoff | Vice President of Group Corporate Communications and IR
+49(0)551.308.1686 | petra.kirchhoff@sartorius.com
Regulatory filing PDF file
Document title: SSB_9M_2017_pre-release_e_final
Document: http://n.eqs.com/c/fncls.ssp?u=XEXUVLALFM [1]
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: News release on accounts, results
End of Announcement EQS News Service
619491 16-Oct-2017 CET/CEST
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a3e626c3dc332bb11e3673aba382617f&application_id=619491&site_id=vwd&application_name=news
(END) Dow Jones Newswires
October 16, 2017 15:17 ET (19:17 GMT)
